Cidara Therapeutics, Inc. (CDTX) Stock Overview
Explore Cidara Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Cidara Therapeutics, Inc. (CDTX)
Key Financials
Key Financials
Market Cap
5.6B
P/E Ratio
-34.54
EPS (TTM)
$-11.20
ROE
-0.37%
CDTX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Cidara Therapeutics, Inc. (NASDAQ: CDTX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Cidara Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CDTX on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $75.91 for the NASDAQ listing.
Key metrics behind Cidara Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -34.54 and a market capitalization of 5.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of CDTX on the NASDAQ.